Syneron Medical Ltd. launched its new PicoWay picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress, held in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015, according to the company.

PicoWay incorporates high peak power and the short pulse durations to create the strongest photo-mechanical impact, which enables the most safe and effective fracturing of tattoo ink or pigmentation, Syneron says. The revolutionary PicoWay technology is integrated into a proven, reliable Candela platform.

PicoWay is CE marked and pending FDA clearance. Syneron anticipates that it will receive FDA clearance for PicoWay by the end of 2014.

Dr. Tina Alster, Clinical Professor of Dermatology at Georgetown University Hospital, and one of the investigators in the multi-center clinical trials conducted with PicoWay, said, "With the shortest pulse on the market, PicoWay requires lower fluences and yields faster clinical results than traditional Q-switched lasers. The Nd:YAG wavelength can safely treat a wider variety of skin types and, along with the reduced fluence, minimizes thermal injury to the skin.  I believe that the PicoWay will further revolutionize tattoo removal."